Abstract
List of participants in the scientific symposium of the Pulmonary Hypertension Academic Research Consortium, Bethesda, Maryland, USA, 30 March-1 April 2012
Group 1: Experience in previous trials to guide future studies
Academia
Ghazwan Butrous, MD, University of Kent
Robyn Barst, MD, Columbia University Medical Center
Nicholas Hill, MD, Tufts Medical Center
David Langleben, MD, McGill University
Regulatory
Abraham Karkowsky, MD, PhD, FDA Division of Cardiovascular and Renal Products
Thomas Marciniak, MD, FDA Division of Cardiovascular and Renal Products
Sue-Jane Wang, PhD, FDA Associate Director, Pharmacogenomics and Adaptive Design
Industry
Neil Davie, Bayer HealthCare Pharmaceuticals Hunter Gillies, MD, Gilead Sciences, Inc. Debbie Quinn, MD, Novartis Pharmaceuticals
Group 2: Clinical endpoint definitions
Academia
Paul Hassoun, MD, Johns Hopkins Medical Center Erika Berman Rosenzweig, MD, Columbia University Medical Center
H. Ardeschir Ghofrani, MD, University of Giessen Lung Center Evangelos Michelakis, MD, University of Alberta Omar Minai, MD, Cleveland Clinic
Ronald Oudiz, MD, David Geffen School of Medicine at UCLA
Regulatory
John Lawrence, PhD, FDA Division of Biometrics I
Gail Moreschi MD, MPH, FDA Division of Cardiovascular and Renal Products
Industry
Sylvia Nikkho, MD, Bayer HealthCare Pharmaceuticals Paula E. Rinaldi, Novartis Pharmaceuticals John Teeter, MD, Pfizer, Inc.
Group 3: Novel clinical trial designs
Academia
Martin Wilkins, MD, Imperial College
Shein-Chung Chow, PhD, Duke University School of Medicine
Andy Grieve, PhD, Aptiv Solutions
Dunbar Ivy, MD, University of Colorado Denver Health Sciences Center
Steven Kawut, MD, University of Pennsylvania Medical Center
Mohammad H. Rahbar, PhD, The University of Texas School of Public Health at Houston
Regulatory
H. M. James Hung, PhD, FDA Office of Biostatistics; Office of Translational Sciences
Shen Xiao MD, PhD, FDA Division of Cardiovascular and Renal Products
Industry
Noreen Henig, MD, Gilead Sciences Inc. Steve Dawe, Novartis Pharmaceuticals Lutz Harnisch, MD, Pfizer Inc.
John Curram, PhD, Bayer HealthCare Pharmaceuticals
Group 4: Anticipated classes of new medications and molecular targets
Academia
Nicholas Morrell, MD, University of Cambridge
Stephen Archer, MD, University of Chicago
Marlene Rabinovitch, MD, Stanford University School of Medicine
Ralph Schermuly, PhD, University of Giessen Lung Center
Kurt Stenmark, MD, University of Colorado
Duncan Stewart, MD, Ottawa Hospital Research Institute
Regulatory
Albert F. De Felice, FDA Division of Cardiovascular and Renal Products
Monica Fiszman, MD, PhD, FDA Division of Cardiovascular and Renal Products
Muriel Saulnier DVM, PhD, FDA Division of Cardiovascular and Renal Drug Products
Industry
Gennyne Walker, PhD, Gilead Sciences Inc. Thomas R. Martin, MD, Novartis Pharmaceuticals Steven Evans PhD, Pfizer Inc.
Hubert Truebel, MD, Bayer HealthCare Pharmaceuticals
Group 5: Fundamental academic standards
Academia
John Newman, MD, Vanderbilt University Medical Center
C. Greg Elliott, MD, University of Utah School of Medicine
J. Simon S. Gibbs, MD, Imperial College London
S. Glennis Haworth, MD, Institute of Child Health, London, UK
Julio Sandoval, MD, National Institute of Cardiology- Ignacio Chávez
Werner Seeger, MD, The Universities of Giessen and Marburg Lung Center
Regulatory
Satjit Brar, PharmD, PhD, FDA Division of Pharmacometrics
Industry
Edio Zampaglione, MD, Bayer HealthCare Pharmaceuticals Cara Cassino, MD, Pfizer Inc.
Pediatric Advisory Committee
Ian Adatia, MD, University of Alberta Abraham Karkowsky, MD, PhD, FDA Division of Cardiovascular and Renal Products Robyn Barst, MD, Columbia University Medical Center
S. Glennis Haworth, MD, Institute of Child Health, London, UK
Dunbar Ivy, MD, University of Colorado Denver Health Sciences Center
Erika Berman Rosenzweig, MD, Columbia University Medical Center
Kurt Stenmark, MD, University of Colorado
Max Wegner, MD, Bayer HealthCare Pharmaceuticals
Chris Aguilar, MD, Gilead Sciences Inc.